Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorlatinib + temozolomide
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lorlatinib + temozolomide is an investigational combination therapy consisting of lorlatinib, a third-generation ALK tyrosine kinase inhibitor, and temozolomide, an alkylating agent. This combination is being studied primarily for patients with ALK-positive cancers who have experienced central nervous system (CNS) progression while on ALK inhibitor therapy. The rationale for this combination is based on temozolomide's CNS penetration capabilities and mechanism of action, which may complement lorlatinib's activity against ALK-positive tumors to provide improved control of CNS disease.
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)DNA
Beyond the preview
Go deeper on lorlatinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorlatinib + temozolomide.